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Abstract 
Background: Osteosarcoma (OS) is the most common cancer of bone. Jaw osteosarcoma (JOS) is rare and it differs 
from other OS in terms of the time of occurrence (two decades later) and better survival. The aim of our work was to 
develop and characterize specific mouse models of JOS.
Methods: Syngenic and xenogenic models of JOS were developed in mice using mouse (MOS‑J) and human 
(HOS1544) osteosarcoma cell lines, respectively. An orthotopic patient‑derived xenograft model (PDX) was also devel‑
oped from a mandibular biopsy. These models were characterized at the histological and micro‑CT imaging levels, as 
well as in terms of tumor growth and metastatic spread.
Results: Homogeneous tumor growth was observed in both the HOS1544 and the MOS‑J JOS models by injection of 
0.25 × 106 and 0.50 × 106 tumor cells, respectively, at perimandibular sites. Histological characterization of the tumors 
revealed features consistent with high grade conventional osteosarcoma, and the micro‑CT analysis revealed both 
osteogenic and osteolytic lesions. Early metastasis was encountered at day 14 in the xenogenic model, while there 
were no metastatic lesions in the syngenic model and in the PDX models.
Conclusion: We describe the first animal model of JOS and its potential use for therapeutic applications. This model 
needs to be compared with the usual long‑bone osteosarcoma models to investigate potential differences in the 
bone microenvironment.
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Background
Osteosarcoma (OS) is the most common cancer of bone 
[1, 2]. Jaw osteosarcoma (JOS) is a rare condition, repre-
senting only 5 to 10 percent of all osteosarcomas [3–5]. It 
differs from long-bone osteosarcomas (LBOS) as it typi-
cally occurs two decades later [5, 6], has a lower meta-
static potential [4], and has better patient survival rates 
[6, 7]. Metastases remain the major cause of death [8]. 
The treatment of JOS is based on the treatment of LBOS, 
and it comprises neoadjuvant chemotherapy followed by 
surgical resection and adjuvant chemotherapy [9, 10]. 
The surgical procedure remains complicated with facial 
locations because it is difficult to obtain free surgical 
margins, thus leading to functional and aesthetic impair-
ments. Radical surgery with wide clear margins is the 
main prognostic factor of the disease [6, 11]. The rarity 
of the disease makes it difficult to carry out early-phase 
clinical trials. There is, therefore, a need for appropriate 
animal models that recapitulate the complexity and the 
heterogeneity of this malignancy [12].
OS is characterized by a lack of recurrent transloca-
tions and a complex karyotype [13]. The tumor sup-
pressor genes p53 and Rb are frequently altered and 
they appear to be involved in initiation of the disease 
[14–16]. It has also been well established that the bone 
microenvironment plays a major role in the development 
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interactions between tumor cells and the host are still 
largely unknown [2]. The generation of specific animal 
models that mimic the human disease would allow for 
a better understanding of the mechanisms involved in 
tumorigenesis and to test new therapeutic agents.
Several OS mouse models have been developed in the 
long bones [19]. But to date, no specific animal model of 
JOS has been carried out, and the biological behaviour 
of these sarcomas appears to differ from LBOS [20]. The 
aim of our work was to develop and characterize specific 
mouse models of JOS.
Methods
Animal housing and handling
Four-week-old female mice (Elevages Janvier, France) 
were housed in groups of four under pathogen-free 
conditions at the Experimental Therapy Unit (Medi-
cal School, Nantes, France) in accordance with French 
institutional guidelines (CEEA.PdL.06, authorization 
no 8405 and 8449). Mice were given access to food and 
water ad  libitum. This report adheres to the EU direc-
tive 2010/63/EU and the ARRIVE Guidelines for report-
ing animal research [22], and a completed checklist is 
included in Additional file 1.
Transplantation of murine and human osteosarcoma cell 
lines
Osteosarcoma cell lines (Additional file 2: Table S1) sus-
pended in PBS solution were inoculated under general 
anaesthesia at a paraosseous site after periosteum scrap-
ing (isoflurane-air mixture, 1.5%, 1 L/min). For ethical 
considerations, mice were euthanized by cervical disloca-
tion when the tumor volume reached 150 mm3.
Three murine (MOS-J, POS-1, and K7-M2) and four 
human (HOS1544, HOS 1547, MG-63, and SaOS-2) 
LBOS cell lines were used. One million cells were injected 
at a mandibular site in 7 groups of 3 mice (C57Bl/6, C3H/
HeN, and Balb/c for the syngenic models, and in NMRI-
nude mice for the xenogenic models). A dose–effect 
study was carried out: 0.25 ×  106, 0.50 ×  106, and 1 ×  106 
MOS-J or HOS1544 cells as a 20 μL suspension in PBS in 
C57Bl/6 and NMRI-nude mice (n = 4/group).
Development of a JOS PDX model from a patient
PDX models were developed from the biopsy of a patient 
exhibiting a JOS. A 1  mm3 fragment of the tumor was 
grafted under the mandibular or the tibial periosse-
ous membrane in two anesthetized SCID mice (xylazine 
8%-ketamine 5% in PBS; 100 μL/10 g). Part of the speci-
men was digested for 2 h at 37 °C in Dulbecco’s modified 
Eagle’s medium (DMEM) (Biowhittaker, Belgium), 10% 
collagenase, and 1% Penicillin 100 U/mL—Streptomycin 
100  mg/L (Invitrogen, France). After centrifugation, the 
cells (hereafter referred to as AT2015 cells) were cultured 
at 37 °C in DMEM/10% FBS, 1% glutamine, and 1% anti-
biotics. The cells were washed in DMEM and then used 
for perimandibular (1 ×  106; 20 μL) and paratibial injec-
tion (2 ×  106; 40 μL).
Tumor growth recordings
Tumor volumes were calculated using the formula  (l2 × 
L)/2, where l is the smallest and L the largest perpendicu-
lar diameter of the tumor.
Micro‑CT analysis
Mandibles were scanned at necropsy using a SkyS-
can-1072 X-ray microcomputed tomography system 
(Bruker, Massachusetts, USA) with the following param-
eters: 18  μm pixel size, 50  kV, 0.5-mm AI filter, and a 
rotation step of 0.7 degrees. Three-dimensional (3D) 
reconstructions and analysis were performed using 
NRecon, CTVox and CTAn 32-bit software (Skyscan). A 
region of interest corresponding to the tumor area was 
defined from the posterior side of the central incisor over 
a length of 5.4  mm. The cortical (BV, BV/TV) and tra-
becular (Tb.Th, Tb.Sp and Tb.N) bone parameters were 
quantitatively compared between tumor mandibles and 
normal jaw in the HOS1544 model.
Histological analysis
Jaws were fixed in 10% buffered formaldehyde and then 
decalcified by electrolysis. After embedding in paraffin, 
3-μm-thick sections were stained with haematoxylin–
eosin (HE) or with Masson trichrome. For the analysis 
of lung metastases, 3  μm-thick sections were generated 
every 300  μm and the tumor foci were quantified using 
NDPView2 Hamamatsu software (SZK, Japan).
Statistical analysis
The statistical analysis was performed with GraphPad 
Prism software for Windows (GraphPad Software, La 
Jolla, USA). A two-factor ANOVA and the unpaired 
Mann–Whitney test were used to compare the tumor 
volumes and the number of metastases, respectively. An 
unpaired Mann–Whitney test and a Wilcoxon test for 
paired observations allowed to analyse the bone param-
eters. Results with P < 0.05 were considered significant.
Results
Development of preclinical models of mouse JOS
All of the mice injected with murine osteosarcoma cells 
developed a mandibular tumor. For the syngenic models, 
the tumor growth was more homogeneous in the MOS-J 
model than POS-1 and K7M2, with a mean tumor vol-
ume of 46.6  mm3 (± 11.5  mm3), 10  mm3 (± 14.1  mm3), 
and 15.3  mm3 (± 11.5  mm3), respectively, at day 11 
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(D11). For the xenogenic models, the most homogeneous 
growth was observed with HOS1544 cells: mean tumor 
volume 60  mm3 (± 20  mm3) at D11 versus 73.3  mm3 
(± 30.5  mm3), 60  mm3 (± 34.6  mm3), and 33.3  mm3 
(± 11.5  mm3) for the MG-63, HOS1547, and SaOs-2 
cells, respectively.
Uniform dose-dependent growth of the mandibular 
tumor was observed in the HOS1544 model (p = 10−4), 
while the MOS-J model was more heterogeneous. The 
most comparable growth was obtained with inoculation 
of 0.25 ×  106 HOS1544 cells and 0.5 ×  106 MOS-J cells, 
respectively (Additional file 2: Figure S1).
PDX models developed at both mandibular and tibial 
sites irrespective of whether a tumor fragment or AT2015 
tumor cells were used. A palpable mass was detected at 
D14 for the tumor graft and D60 for the tumor cell inoc-
ulation. The tumor volume reached 100 mm3 at D30 and 
at D75 for the respective models.
Characterization of the JOS models
Histological analysis
Histological examination confirmed the diagnosis of 
high grade conventional osteosarcomas exhibiting mul-
tiple osteoblastic tumor cells, with polymorphic nuclei, 
thin chromatin, and large nucleoli. Areas of intratumoral 
necrosis were often observed, together with several 
mitoses irrespective of whether xenogenic (Fig. 1) or syn-
genic (Fig. 2) models were being studied.
The PDX models were compared with the human 
parental tumor, exhibiting very similar lesions, irrespec-
tive of the use of a tumor fragment or tumor cell injection 
(Fig.  3). This analysis revealed high grade osteosarcoma 
features with osteoblastic tumor cells that secreted an 
osteoid substance and that had various nuclear atypia 
with a high mitotic index and focal areas of chondroblas-
tic differentiation.
Micro‑CT analysis
The bone lesions were comparable between the murine 
models and the human disease. A high prevalence 
of mandibular osteolytic lesions was observed in the 
HOS1544 and the AT2015-induced PDX models. More 
osteogenic features were noted in the MOS-J model 
and in the PDX induced with a human tumor frag-
ment  (Fig.  4a, b). The quantitative analysis of bone 
parameters in the HOS1544 model in comparison with 
contralateral normal mandible in mice showed a trend of 
tumor induced bone lysis, as revealed by the decrease of 
BV, BV/TV, Tb.Th, Tb.N and the increase of Tb.Sp but 
with non-statistical significance (Table 1).
Large osteogenic lesions with a high level of periosteal 
reaction were observed in the PDX models induced in 
long bones, particularly those induced with AT2015 
tumor cells (Fig. 4c).
Tumor growth and metastatic spread in lungs
The mandibular tumor grew significantly faster in the 
xenogenic HOS1544 JOS model compared to the syn-
genic MOS-J model, with the tumor volume reach-
ing 100  mm3 at D14 versus D23, respectively  (Fig.  5a). 
There was substantial metastatic spread in lungs in the 
HOS1544 JOS model, with a mean number of metastases 
Fig. 1 Masson’s trichrome staining of a section of a mandibular osteosarcoma developed in an NMRI‑nude mouse (HOS1544 model) in a frontal 
view (left, original magnification (OM)). Note the large tumor (T) with local invasion of the cortical and medullary mandibular bone (MB), and 
substantial central tumor necrosis (black arrows) (right, OM × 5). The osteoblastic tumor cells present with several mitoses and produce intercellular 
osteoïd substance (window, OM x 20)
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Fig. 2 Masson’s trichrome staining of a section of a mandibular osteosarcoma developed in C57Bl/6 mouse (MOS‑J model) in a frontal view (left, 
original magnification (OM)). Large tumor (T) developed in contact with left mandibular bone (MB) (right, OM × 5). High density of osteoblastic 
tumor cells secreting osteoïd substance (window, OM × 20)
Fig. 3 Histological comparison of the osteosarcoma parental tumor (PT) (left) with the PDX models derived from a tumor fragment (TF) (middle) 
and from the AT2015 tumor cells (TC) (right) (OM × 20). Conventional osteosarcoma features with osteoblastic tumor cells in an osteoid stroma, 
various nuclear atypia with high mitotic index. The rare areas of chondroblastic differentiation are not showed in this section
Table 1 Cortical (BV, BV/TV) and  trabecular (Tb.Th, Tb.Sp, Tb.N) bone parameters measured in  tumor and  contralateral 
(normal) mandibles
N number of animals, SD standard deviation
Tumor jaw (n = 8) Normal jaw (n = 8)
Bone volume (BV), mean ± SD (mm3) 12.64 ± 1.21 13.09 ± 0.27
BV/Tumor volume (BV/TV) 61.17 ± 7.09 66.57 ± 0.96
Trabecular thickness (Tb.Th), mean ± SD (mm) 0.29 ± 0.02 0.30 ± 0.01
Trabecular separation (Tb.Sp), mean ± SD (mm) 0.27 ± 0.04 0.24 ± 0.01
Trabecular number (Tb.N), mean ± SD 2.09 ± 0.17 2.22 ± 0.03
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of 5.6 (0-12) per mouse at D14. This value did not cor-
relate with the mean tumor volume. Most of the lung 
lesions were macroscopically visible  (Fig.  5b). Neither 
lung metastases could be discerned in the MOS-J JOS 
model at D23, nor in the PDX models. 
Discussion
As the survival rate for osteosarcoma has not changed 
over the past 40  years [19, 23, 24], the development 
of new and more effective therapeutic approaches, as 
assessed with relevant preclinical models [25], is urgently 
needed [12].
An ideal animal model of osteosarcoma should reca-
pitulate all of the aspects of the human pathology, from 
the genetic events to the functional osteoid matrix pro-
duction by osteosarcoma cells [2], and it should also dis-
seminate spontaneously to the lungs [8]. To date, several 
OS mice models have been developed in the long bones 
[19]. They are induced by different approaches; radia-
tion- and chemically induced mouse models refer to 
DNA damage studies [2, 13], while genetically engineered 
mouse (GEM) models have been induced by deletion of 
p53 and Rb in the osteoblast lineage [23, 26], as well as 
by overexpression of oncogenes in osteoblastic precur-
sors [27]. These models help with gaining a better under-
standing of the molecular mechanisms involved in tumor 
initiation [24], but they remain heterogeneous in terms 
of specificity, incidence, and tumor latency [26]. Tumor 
cell graft models are routinely used in mice, as they are 
easy to set-up, affordable, and reproducible [2, 13, 19, 
25]. They allow for a better understanding of the mecha-
nisms involved in tumor and metastatic progression [13]. 
Patient-Derived Xenograft (PDX) models based on graft-
ing of neoplastic cells or tissues obtained from patients in 
immunodeficient mice [8, 28] appear to better reproduce 
the tumor microenvironment and allow a wide range of 
drugs to be tested by means of a personalized approach 
for patients [29–31]. In regard to our study, the HOS1544 
and MOS-J cell lines have been reported to induce a pri-
mary tumor after paratibial or intraosseous injection in 
nude mice and C57Bl/6 mice, respectively, and to allow 
for spontaneous lung metastasis [19, 32]. Unfortunately, 
these models do not, however, recapitulate tumor initia-
tion and they do not account for the impact of the bone 
microenvironment, particularly the immune response 
that occurs in xenogenic models [2, 13].
We here describe the first JOS model in non-genetically 
modified mice, induced by inoculation of HOS1544 and 
MOS-J cells in close contact with the mandible. These 
models were found to reproduce the same histological 
and morphometric characteristics of the human disease 
at the jaw site. Early metastatic spread was observed in 
the HOS1544 model, as well as fast and homogeneous 
tumor growth, as previously described for LBOS mod-
els and correlated with the high level of aggressiveness 
of this cell line [33]. However, for ethical considerations, 
early euthanasia of the animals has to be performed when 
Fig. 4 Micro‑CT analysis of the xenogenic HOS1544 and syngenic 
MOS‑J JOS models (a). Micro‑CT characterization of the JOS (b) and 
tibial OS (c) PDX models
Page 6 of 8Bertin et al. J Transl Med           (2019) 17:56 
the tumor volume reaches 150 mm3 at the jaw site, while 
a 1500 mm3 tumor volume is acceptable in long bones.
We concomitantly developed orthotopic PDX mod-
els of jaw osteosarcoma in SCID mice, which, to our 
knowledge, represents the first description at a mandibu-
lar location. The main advantage of this model is that it 
preserves the native tumor microenvironment, allowing 
primary tumor formation and the early stage of meta-
static progression to be studied [13, 28]. PDX models are 
particularly valuable with rare cancers, due to the small 
number of patients eligible for evaluation of experimental 
therapies and the possibility to test personalized treat-
ments [30, 31]. Some limitations arise due to the need 
for a sufficient amount of fresh tissue and the technical 
ability to achieve engraftment, which is a lengthy process 
that suffers from a low rate of success and high cost [12, 
28, 29, 31]. Although PDX have an identical genomic pro-
file as the original tumor [25], a careful histologic analysis 
of PDX and their parental tumors is recommended prior 
to their use in preclinical analyses [12].
OS is a malignant tumor of mesenchymal origin that 
simultaneously generated osteolytic lesions and mineral-
ized osteoid matrix, thereby resulting in mixed lytic/blas-
tic lesions. The bone-morphometric parameters of our 
models were investigated by micro-CT in order to ana-
lyse the functional behaviour of the tumors. Osteogenic 
lesions were observed in the MOS-J-induced mice and 
osteolytic lesions in the HOS1544, POS-1, and K7M2 
models, in accordance with those previously reported in 
the respective paratibial models.
The differences observed in the clinical and biologi-
cal behaviour between the two sites may be due to dif-
ferent microenvironments, although there have been 
very few studies to date comparing the tumor microen-
vironment in LBOS versus JOS [34, 35]. Vascularization 
could play an important role since immunohistochemical 
studies have revealed a significantly lower level of VEGF 
expression in JOS compared to LBOS samples, which 
may explain a lower metastatic potential of the jaw site 
[34]. In addition, differences in the periosteal reaction 
observed in the PDX models, whether the AT2015 tumor 
cells were injected at tibial or mandibular sites, can be 
explained by variations in the equilibrium between bone 
formation and resorption at the tumor site.
Further studies are hence needed to assess the role of 
the jaw microenvironment in osteosarcoma development 
by investigation of the immune response to tumor ini-
tiation, vascularization, and bone remodelling. Our new 
JOS models could prove to be a key resource for such 
studies and for testing of new therapeutic agents.
Conclusion
We described the first animal model of JOS and its poten-
tial use in therapeutic applications. This model needs to 
be compared with conventional long-bone osteosarcoma 
models to investigate potential bone microenvironment 
differences.
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